You do not currently have access to this content.
Although antibody–drug conjugates (ADC) have transformed the standard of care for patients with metastatic urothelial carcinoma, primary and acquired resistance remain major obstacles to achieving ...
CAR T-cell therapies have the potential to effectively redirect antitumor immunity and elicit long-term responses, but clinical benefit is often limited by T-cell exhaustion, among other factors.
Cancer Res (2026) 86 (8_Supplement): LB407.
Thermo Fisher Scientific, Carlsbad, CA.
Spevatamig (PT886) is an IgG1-based bispecific antibody targeting tumor cells expressing claudin 18.2 (CLDN18.2) and/or CD47 to mediate enhanced anti-tumor activity through innate immune cell and ...
Abstract. ADAM9 (A Disintegrin And Metalloproteinase 9) is a transmembrane metalloproteinase overexpressed in a wide range of solid tumors, where it promotes tumor progression, metastasis, and poor ...
Search for other works by this author on: ...
Search for other works by this author on: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results